Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab + Chemotherapy in Japanese Patients with Advanced Esophageal Squamous Cell Carcinoma
NCT07733180Phase 2Recruiting
- Sponsor
- BeOne Medicines
- Start
- Sep 2026
- Primary completion
- Feb 2028
- Countries
- 1
01
Overview
A Phase 2 trial of tislelizumab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by BeOne Medicines. Started Sep 2026; status: recruiting.
02
Drugs
tislelizumab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT07733180.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07733180.